FDAnews
www.fdanews.com/articles/174593-advaxis-anal-cancer-candidate-wins-orphan-status-in-eu

Advaxis’ Anal Cancer Candidate Wins Orphan Status in EU

December 18, 2015

It’s been a good month for Princeton, N.J.-based Advaxis in the EU, which has been granted orphan status for two cancer candidates.

Last week, Advaxis announced that the European Medicines Agency had awarded the status to the company’s anal cancer candidate axalimogene filolisbac. The agency recently awarded the same status to the company’s ADXS-HER2 for the treatment of osteosarcoma.

As a result of these decisions, Advaxis is eligible to receive market exclusivity for a period of up to 10 years for each candidate.